AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Financial Results | Sanofi 2024 Full Year Revenue EUR 44286.00 Million Net Income EUR 5618.00 Million
ByAinvest
Thursday, Feb 13, 2025 9:00 pm ET1min read
Sanofi(SNY) posted the Q4 of its 2024 financial results on 2/13/2025, reporting total revenue of EUR 44286.00 million for the year, up 6.41% from EUR 41618.00 million year over year, reporting net income of EUR 5618.00 million for the year, up 3.35% from EUR 5436.00 million year over year. The EPS is EUR 4.44 for the year, compare with EUR 4.31 last period.
[Detailed Data]
| Million EUR | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Total Revenue | 11420.00 | 14157.00 | 11380.00 | 11118.00 |
| Cost of Sales | 3576.00 | 4085.00 | 3410.00 | 3439.00 |
| Gross Profit | 7844.00 | 10072.00 | 7970.00 | 7679.00 |
| Total Operating Expenses | 6783.00 | 6569.00 | 6578.00 | 6332.00 |
| Operating Income | 1061.00 | 3503.00 | 1392.00 | 1347.00 |
| Net Income | 695.00 | 2844.00 | 1117.00 | 1146.00 |
| Net Income Attributable to Common Shareholders | 683.00 | 2815.00 | 1113.00 | 1133.00 |
| EPS(EUR) | 0.54 | 2.25 | 1.7578 | 0.91 |
[Company Profile]
Sanofi was incorporated under the laws of France in 1994. The company is a leading global healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The company's activities are organized around the following categories: DUPIXENT, Neurology & Immunology, Rare Diseases, Oncology, Rare Blood Disorders, General Medicines Core Assets and Non-Core Assets, Vaccines, and CHC.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet